Next Article in Journal
Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients
Next Article in Special Issue
Anaplastic Lymphoma Kinase in Cutaneous Malignancies
Previous Article in Journal
Exploring the Role of RGD-Recognizing Integrins in Cancer
Previous Article in Special Issue
ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(9), 118; doi:10.3390/cancers9090118

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Raymond Lai
Received: 9 August 2017 / Revised: 24 August 2017 / Accepted: 31 August 2017 / Published: 5 September 2017
(This article belongs to the Special Issue Targeting ALK in Cancer)
View Full-Text   |   Download PDF [358 KB, uploaded 5 September 2017]   |  

Abstract

Since the discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas in 2007, and the subsequent identification of at least 15 different variants in lung cancers, there has been a revolution in molecular-targeted therapy that has transformed the outlook for these patients. Our recent focus has been on understanding how and why the expression of particular variants can affect biological and molecular properties of cancer cells, as well as identifying the key signalling pathways triggered, as a result. In the clinical setting, this understanding led to the discovery that the type of variant influences the response of patients to ALK therapy. Here, we discuss what we know so far about the EML4-ALK variants in molecular signalling pathways and what questions remain to be answered. In the longer term, this analysis may uncover ways to specifically treat patients for a better outcome. View Full-Text
Keywords: anaplastic lymphoma kinase; echinoderm microtubule-associated protein; non-small cell lung cancer; tyrosine kinase inhibitor anaplastic lymphoma kinase; echinoderm microtubule-associated protein; non-small cell lung cancer; tyrosine kinase inhibitor
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Sabir, S.R.; Yeoh, S.; Jackson, G.; Bayliss, R. EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. Cancers 2017, 9, 118.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top